Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Austin R. Dosch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9071-1591; OpenAlex author ID A5089529776. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 14

  1. CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis. Co-author DOI 10.1016/j.jcmgh.2025.101606↗
  2. Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer Co-author DOI 10.64898/2025.12.04.691935↗
  3. Tumor Cell-Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-23-1200↗
  4. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1046↗
  5. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-22-0329↗
  6. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02368-w↗
  7. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overco… Co-author DOI 10.1053/j.gastro.2022.07.076↗
  8. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-19-1043↗
  9. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0083↗
  10. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-19-0741↗
  11. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-18-0464↗
  12. Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.26621↗
  13. New mechanistic insights into modifiable risk factors that promote pancreatic cancer. First author DOI 10.18632/oncotarget.26813↗
  14. Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-0579↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nagaraj S. Nagathihalli · 14 shared papers, 2018–2025 · strength 1.84
  2. Nipun B. Merchant · 13 shared papers, 2018–2025 · strength 1.68
  3. Siddharth Mehra · 10 shared papers, 2020–2025 · strength 1.43
  4. Supriya Srinivasan · 9 shared papers, 2018–2025 · strength 1.19
  5. Iago De Castro Silva · 7 shared papers, 2021–2025 · strength 1.02
  6. Samara P. Singh · 7 shared papers, 2021–2025 · strength 1.02
  7. Jashodeep Datta · 5 shared papers, 2022–2024 · strength 0.71
  8. Haleh Amirian · 4 shared papers, 2023–2025 · strength 0.69
  9. Michael Nathan VanSaun · 5 shared papers, 2018–2025 · strength 0.57
  10. Anna Bianchi · 3 shared papers, 2023–2025 · strength 0.50
  11. Jashodeep Datta · 3 shared papers, 2021–2025 · strength 0.50
  12. Jason A. Castellanos · 4 shared papers, 2018–2021 · strength 0.37
  13. Tulasigeri M. Totiger · 3 shared papers, 2018–2025 · strength 0.35
  14. Peter J. Hosein · 2 shared papers, 2022 · strength 0.24
  15. Christine Isabelle Rafie · 2 shared papers, 2022–2023 · strength 0.24
  16. Nilesh Deshpande · 2 shared papers, 2022–2023 · strength 0.24
  17. Brent A. Willobee · 2 shared papers, 2020–2021 · strength 0.23
  18. Kathleen E. DelGiorno · 1 shared paper, 2025 · strength 0.19
  19. Oliver Gene McDonald · 1 shared paper, 2025 · strength 0.19
  20. Vineet Kumar Gupta · 1 shared paper, 2025 · strength 0.19
  21. Chanjuan Shi · 2 shared papers, 2018–2019 · strength 0.17
  22. Eli Gilboa · 1 shared paper, 2023 · strength 0.16
  23. William L. Hwang · 1 shared paper, 2023 · strength 0.12
  24. Ifeanyichukwu Chinedu Ogobuiro · 1 shared paper, 2023 · strength 0.12
  25. Carina Shiau · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.